ethyl 2-(4-chlorophenyl)-2-cyclopentyl-2-hydroxyacetate | 741682-85-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 2-(4-chlorophenyl)-2-cyclopentyl-2-hydroxyacetate
• 英文别名: Ethyl 4-chloro-I+/--cyclopentyl-I+/--hydroxybenzeneacetate
• CAS: 741682-85-9
• 化学式: C₁₅H₁₉ClO₃
• 分子量: 282.767
• InChiKey: YNBNVUNSCIMHGL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 2-(4-chlorophenyl)-2-cyclopentyl-2-hydroxyacetate 在 水 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 39.0h， 生成 2-[(4-chlorophenyl)-2-cyclopentyl-2-hydroxyacetoxy]-1,1-dimethylpyrrolidinium iodide
  参考文献：
  名称：

  Carry Over of Impurities: A Detailed Exemplification for Glycopyrrolate (NVA237)

  摘要：

  The original synthesis of glycopyrrolate (NVA237) was revised and shortened into an essentially one-pot process. Without isolating the intermediates, their purification became obsolete, thereby increasing the possibility of the carry over of impurities. For that reason, the actual, potential, and theoretical impurities of the starting materials cyclopentyl mandelic acid and 1-methyl-pyrrolidin-3-ol as well as byproducts which may occur during the synthesis were thoroughly investigated; furthermore, their transformation to possible impurities in the drug substance along the new synthetic route was performed to exclude them as actual impurities in the drug substance with certainty. The question is raised how detailed such investigation-which are fairly manageable for a simple product like glycopyrrolate-need to be.

  DOI：

  10.1021/op3001788
• 作为产物：
  描述：

  环戊基(氧代)乙酸乙酯 、 4-氯苯基溴化镁 以 四氢呋喃 、 乙醚 为溶剂， 反应 1.5h， 生成 ethyl 2-(4-chlorophenyl)-2-cyclopentyl-2-hydroxyacetate
  参考文献：
  名称：

  Carry Over of Impurities: A Detailed Exemplification for Glycopyrrolate (NVA237)

  摘要：

  The original synthesis of glycopyrrolate (NVA237) was revised and shortened into an essentially one-pot process. Without isolating the intermediates, their purification became obsolete, thereby increasing the possibility of the carry over of impurities. For that reason, the actual, potential, and theoretical impurities of the starting materials cyclopentyl mandelic acid and 1-methyl-pyrrolidin-3-ol as well as byproducts which may occur during the synthesis were thoroughly investigated; furthermore, their transformation to possible impurities in the drug substance along the new synthetic route was performed to exclude them as actual impurities in the drug substance with certainty. The question is raised how detailed such investigation-which are fairly manageable for a simple product like glycopyrrolate-need to be.

  DOI：

  10.1021/op3001788

文献信息

• MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS CONTAINING PIPERIDINE DERIVATIVES AS THE ACTIVE INGREDIENT
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP1595867A1

  公开（公告）日：2005-11-16

  The invention provides melanin-concentrating hormone receptor antagonists containing as the active ingredient piperidine derivatives represented by the general formula [I]:    [wherein R1 is hydrogen, hydroxyl, lower alkyl, or the like; R2, R3a, R3b, R4a, R4b, R5a, R5b and R6 each stands for hydrogen, halogen, or the like; W1 and W2 each independently stands for -O-, -CH2-, or the like; Y1, Y2, Y3 and Y4 stand for -CH-, -CF-, -N-, or the like; Z stands for lower alkyl, an aliphatic heterocyclic group, or the like; Ar is a mono- or bi-cyclic aliphatic heterocycle or an aromatic heterocycle; and n is an integer of 1 to 8]. The compounds act as antagonist against melanin-concentrating hormone receptor and are useful as drugs for central diseases, circulatory diseases, or metabolic diseases.

  本发明提供了含有通式[I]代表的哌啶衍生物作为活性成分的黑色素浓缩激素受体拮抗剂： [其中R1为氢、羟基、低级烷基或类似物；R2、R3a、R3b、R4a、R4b、R5a、R5b和R6各自代表氢、卤素或类似物；W1和W2各自独立地代表-O-、-CH2-或类似物；Y1、Y2、Y3 和 Y4 分别代表-CH-、-CF-、-N-或类似物；Z 代表低级烷基、脂族杂环基团或类似物；Ar 是单环或双环脂族杂环或芳香族杂环；以及 n 是 1 至 8 的整数]。这些化合物是黑色素浓缩激素受体的拮抗剂，可作为治疗中枢疾病、循环系统疾病或代谢疾病的药物。
• EP1595867
  申请人：——

  公开号：——

  公开（公告）日：——
• Carry Over of Impurities: A Detailed Exemplification for Glycopyrrolate (NVA237)
  作者：Thomas Allmendinger、Dominique Bixel、Adrian Clarke、Laura Di Geronimo、Jean-Wilfried Fredy、Marco Manz、Elena Gavioli、Regine Wicky、Martin Schneider、Fabien J. Stauffert、Markus Tibi、Darko Valentekovic

  DOI：10.1021/op3001788

  日期：2012.11.16

  The original synthesis of glycopyrrolate (NVA237) was revised and shortened into an essentially one-pot process. Without isolating the intermediates, their purification became obsolete, thereby increasing the possibility of the carry over of impurities. For that reason, the actual, potential, and theoretical impurities of the starting materials cyclopentyl mandelic acid and 1-methyl-pyrrolidin-3-ol as well as byproducts which may occur during the synthesis were thoroughly investigated; furthermore, their transformation to possible impurities in the drug substance along the new synthetic route was performed to exclude them as actual impurities in the drug substance with certainty. The question is raised how detailed such investigation-which are fairly manageable for a simple product like glycopyrrolate-need to be.